[1]
Bajgar, J. Organophosphates/nerve agent poisoning: Mechanism of action, diagnosis, mprophylaxis and treatment. Adv. Clin. Chem., 2004, 38, 151-216.
[2]
Bajgar, J. The Effect of Organophosphates/Nerve Agents: Poisoning
and its Treatment in Schematic Figures and Tables Elsevier, 2012. Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris,
San Diego, San Francisco, Singapore, Sydney, Tokyo.
[3]
Bajgar, J.; Fusek, J.; Kassa, J.; Kuca, K.; Jun, D. Chemical aspects of pharmacological prophylaxis against nerve agent poisoning. Curr. Med. Chem., 2009, 16, 2977-2986.
[4]
Benschop, H.P.; De Jong, L.P.A. Toxicokinetics of nerve agents. In: Somani, S.M.; Romano, J.A., Eds.;Chemical Warfare Agents: Toxicity at Low Levels; CRC Press: Boca Raton, FL, USA, 2001; pp. 25-81.
[5]
Wiesner, J.; Kriz, Z.; Kuca, K.; Jun, D.; Koca, J. Acetylcholinesterases - The structural similarities and differences. J. Enzyme Inhib. Med. Chem., 2007, 22, 417-424.
[7]
Kassa, J.; Musilek, K.; Karasova, J.Z.; Kuca, K.; Bajgar, J. Two possibilities how to increase the efficacy of antidotal treatment of nerve agent poisonings. Mini Rev. Med. Chem., 2012, 12, 24-34.
[8]
Kuca, K.; Jun, D.; Musilek, K.; Pohanka, M.; Zdarova Karasova, J.; Soukup, O. Prophylaxis and post-exposure treatment of intoxications caused by nerve agents and organophosphorus pesticides. Mini Rev. Med. Chem., 2013, 13, 2102-2115.
[9]
Lotti, M. Organophosphorus compounds. In: Experimental and Clinical Neurotoxicology; Spencer, P.S.; Schaumburg H.H. Eds.;2nd Edition, Oxford University Press, New York. , 2000; pp. 898-925.
[10]
Marrs, T.C.; Maynard, R.L.; Sidell, F.R. Chemical Warfare Agents. Toxicology and Treatment., John Wiley and Sons, Chicester,. 1996.
[11]
Kalasz, H.; Hasan, M.Y.; Sheen, R.; Kuca, K.; Petroianu, G.; Ludanyi, K.; Gergely, A.; Tekes, K. HPLC analysis of K-48 concentration in plasma. Anal. Bioanal. Chem., 2006, 385, 1062-1067.
[12]
Rice, H. Toxicology of organophosphorus nerve agents. Issues Toxicol., 2016, 2016(26), 81-116.
[13]
Vale, A.; Marrs, T.C.; Rice, P. Chemical terrorism and nerve agents. Medicine , 2007, 35, 573-575.
[14]
Bajgar, J.; Fusek, J.; Kassa, J.; Kuca, K.; Jun, D. Pharmacological prophylaxis against nerve agent poisoning: experimental studies and practical implications. In: Handbook of Toxicology of Chemical
Warfare Agents; Second Edition, R.C. Gupta, R.C. Ed. Elsevier/
AP, Amsterdam, Boston, Heidelberg, London, New York, Oxford,
Paris, San Diego, San Francisco, Singapore, Sydney, Tokyo, 2015; pp. 979-987.
[15]
Jokanovic, M. Current understanding of the mechanisms involved in metabolic detoxification of warfare nerve agents. Toxicol. Lett., 2009, 188, 1-10.
[16]
Layish, I.; Krivoy, A.; Rotman, E.; Finkelstein, A.; Tashma, Z.; Yehezkelli, Y. Pharmacologic prophylaxis against nerve agent poisoning. Isr. Med. Assoc. J., 2005, 7, 182-187.
[17]
Patočka, J.; Jun, D.; Bajgar, J.; Kuca, K. Prophylaxis against nerve agent intoxications. Def. Sci. J., 2006, 56, 775-784.
[18]
Ramalho, T.C.; de Castro, A.A.; Silva, D.R.; Silva, M.C.; Franca, T.C.C.; Bennion, B.J.; Kuca, K. Computational enzymology and organophosphorus degrading enzymes: promising approaches toward remediation technologies of warfare agents and pesticides. Curr. Med. Chem., 2016, 23, 1041-1061.
[20]
Cabal, J. Providing of the Czech Army by antidotes against chemical
warfare agents Workshop of the laboratory assistants of the 31.
brchbo,, 2016. Liberec, Czech Republic, January 30-31, 2013
[21]
Thors, L.; Koch, B.; Koch, M.; Hagglund, I.; Bucht, A. Comparison of skin decontamination methods following exposure of organophosphorus compounds. 12th International Symposium on Protection against Chemical and Biological Warfare Agents, 2016Stockholm, Sweden8-10 June 2016 Abstracts, p. 77.
[22]
Bajgar, J.; Fusek, J.; Patocka, J.; Hrdina, V. The use of peritoneal dialysis in experimental intoxications with organophosphates. Sbor. Ved. Prac. LF UK (Hradec Kralove), 1982, 25, 319-326.
[23]
Darvesh, S.; Hopkins, D.A.; Geula, C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci., 2003, 4, 131-138.
[24]
Cerasoli, D.M.; Griffiths, E.M.; Doctor, B.P.; Saxena, A.; Fedorko, J.M.; Greig, N.H.; Yu, Q.S.; Huang, Y.; Wilgus, H.; Karatzas, C.N.; Koplovitz, I.; Lenz, D.E. In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem. Biol. Interact., 2005, 157, 363-365.
[25]
Huang, Y-J.; Huang, Y.; Baldassarre, H.; Wang, B.; Lazaris, A.; Leduc, M.; Bilodeau, A.S.; Bellemare, A.; Cote, M.; Herskovits, P.; Touati, M.; Turcotte, C.; Valeanu, L.; Lemée, N.; Wilgus, H.; Bégin, I.; Bhatia, B.; Rao, K.; Neveu, N.; Brochu, E.; Pierson, J.; Hockley, D.K.; Cerasoli, D.M.; Lenz, D.E.; Karatzas, C.N.; Lagermann, S. Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc. Natl. Acad. Sci. USA, 2007, 104, 13603-13608.
[26]
Saxena, A.; Doctor, B.P.; Sun, W.; Luo, C.; Bansal, R.; Naik, R.S.; Fedorko, J.M.; Koplovitz, I.; Maxwell, D.M.; Lenz, D.E.; Ross, M.C. (2004) HuBChE: A bioscavanger for protection against organophosphate chemical warfare agents. U.S. Army Med. Dep. J., 2004, 7, 22-29.
[27]
Sevelova, L.; Bajgar, J.; Saxena, A.; Doctor, B.P. Protective effect of equine butyrylcholinesterase in inhalation intoxication of rats with sarin: Determination of blood and brain cholinesterase activities. Inhal. Toxicol., 2004, 16, 531-536.
[28]
Clark, M.G.; Saxena, A.; Anderson, S.M.; Sun, W.; Bansal, R.; Myers, T.M.; Doctor, B.P. Behavioral toxicity of purified human
serum butyrylcholinesterase in mice. The 4th International
CBMTS,, 2002. 28 April-3 May 2002, Spiez, Switzerland, Abstract
No 19.
[29]
Doctor, B.P.; Raveh, L.; Wolfe, A.D.; Maxwell, D.M.; Ashani, Y. Enzymes as pretreatment drugs for organophosphate toxicity. Neurosci. Biobehav. Rev., 1991, 15, 123-128.
[30]
Doctor, B.P.; Maxwell, D.M.; Saxena, A. Preparation and characterization of bioscavengers for possible use against organophosphate toxicity; M-CB Med. Treat. Sympos, 1997, pp. 26-30.
[31]
Doctor, B.P.; Saxena, A.; Clark, M.G.; Bansal, R.; Luo, C.; Rosenberg, Y.; Lenz, D.; Ashani, Y. Scavenger protection against organophosphates
by human serum butyrylcholinesterase. The 4th International
CBMTS, 2002, 28.
[32]
Saxena, A.; Sun, W.; Fedorko, J.M.; James, M.; Koplovitz, I.; Doctor, B.P. Prophylaxis with human serum butyrylcholinesterase protects guinea pigs exposed to multiple lethal doses of soman or VX. Biochem. Pharmacol., 2011, 81, 164-169.
[33]
Mazur, A. An enzyme in animal tissues capable of hydrolyzing the phosphrous-fluorine bond of alkyl fluorophosphates. J. Biol. Chem., 1946, 164, 271.
[34]
Gupta, R.D.; Goldsmith, M.; Ashani, Y.; Simo, Y.; Mullokandov, G.; Bar, H.; Ben-David, M.; Leader, H.; Margalit, R.; Silman, I.; Sussman, J.L.; Tawfik, D.S. Directed evolution of hydrolases for prevention of G-type nerve agent intoxication. Nat. Chem. Biol., 2011, 7, 120-125.
[35]
Li, W.F.; Furlong, C.E.; Costa, L.G. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol. Lett., 1995, 76, 219-226.
[36]
Raveh, L.; Segall, Y.; Leader, H.; Rothschild, N.; Levanon, D.; Henis, Y.; Ashani, Y. Protection against tabun toxicity in mice by prophylaxis with an enzyme hydrolyzing organophosphate esters. Biochem. Pharmacol., 1992, 44, 397-400.
[37]
Trovasler-Leroy, M.; Musilova, L.; Renault, F.; Brazzolotto, X.; Misik, J.; Novotny, L.; Froment, M.T.; Gillon, E.; Loiodice, M.; Verdier, L.; Masson, P.; Rochu, D.; Jun, D. Organophosphate hydrolases as catalytic bioscavengers of organophosphorus nerve agents. Toxicol. Lett., 2011, 206, 14-23.
[38]
Masson, P.; Josse, O.; Lockridge, O.; Viguie, N.; Taupin, C.; Buhler, C. Enzymes hydrolyzing organophosphates as potential catalytic scavengers against organophosphate poisoning. J. Physiol. Paris, 1998, 92, 357-362.
[39]
Aharoni, A.; Gaidukov, L.; Yagur, S.; Toker, L.; Silman, I.; Tawfik, D.S. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc. Natl. Acad. Sci. USA, 2004, 101, 482-487.
[40]
Ashani, Y.; Goldsmith, M.; Leader, H.; Silman, I.; Sussman, J.L.; Tawfik, D.S. In vitro detoxification of cyclosarin in human blood pre-incubated ex vivo with recombinant serum paraoxonase. Toxicol. Lett., 2011, 206, 24-28.
[41]
Bajaj, P.; Tripathy, R.K.; Aggarwal, G.; Datusalia, A.K.; Sharma, S.S.; Pande, A.H. Refolded recombinant human paraoxonase 1 variant exhibits prophylactic activity. Appl. Biochem. Biotechnol., 2016, 180, 165-176.
[42]
Rochu, D.; Chabriere, E.; Masson, P. Human paraoxonase: A promising approach for pre-treatment and therapy of organophosphorus poisoning. Neurochem. Res., 2008, 33, 348-354.
[43]
Valiyaveettil, M.; Alamneh, Y.; Rezk, P.; Perkins, M.W.; Sciuto, A.M.; Doctor, B.P.; Nambiar, M.P. Recombinant paraoxonase 1 protects against sarin and soman toxicity following microinstuillation inhalation exposure in guinea pigs. Toxicol. Lett., 2011, 202, 203-208.
[44]
Valiyaveettil, M.; Alamneh, Y.; Rezk, P.; Biggemann, L.; Perkins, M.W.; Sciuto, A.M.; Doctor, B.P.; Nambiar, M.P. Protective efficacy of catalytic bioscavenger, paraoxonase 1 against sarin and soman exposure in guinea pigs. Biochem. Pharmacol., 2011, 81, 800-809.
[45]
Jun, D.; Musilova, L.; Kuca, K.; Kassa, J.; Bajgar, J. Potency of several oximes to reactivate human acetylcholinesterase and butyrylcholinesterase inhibited by paraoxon in vitro. Chem. Biol. Interact., 2008, 175, 421-424.
[46]
Jun, D.; Musilova, L.; Musilek, K.; Kuca, K. In vitro ability of currently available oximes to reactivate organophosphate pesticide-inhibited human acetylcholinesterase and butyrylcholinesterase. Int. J. Mol. Sci., 2011, 12, 2077-2087.
[47]
Kovarik, Z.; Katalinic, M.; Sinko, G.; Binder, J.; Holas, O.; Jung, Y.S.; Musilova, L.; Jun, D.; Kuca, K. Pseudo-catalytic scavengeing: Searching for a suitable reactivator of phosphorylated butyrylcholinesterase. Chem. Biol. Interact., 2010, 187, 167-171.
[48]
Sterri, S.H.; Valdal, G.; Lyngaas, S.; Odden, E.; Malthe-Sørenssen, D.; Fonnum, F. The mechanism of soman detoxification in perfused rat liver. Biochem. Pharmacol., 1983, 32, 1941-1943.
[49]
Jokanovic, M. Liver esterases and soman toxicity in the rat following partial hepatectomy. Biochem. Pharmacol., 1990, 39, 797-799.
[50]
Skopec, F.; Bajgar, J. Changes of acetylcholinesterase activity in hepatectomized rats following soman poisoning. Sbor. Ved. Pr. LF UK Hradec Kralove, 1992, 35, 247-252.
[51]
Skopec, F.; Bajgar, J. Anticholinesterase action of organophosphates: importance of the liver. Sbor. Ved. Pr. LF UK Hradec Kralove, 1993, 36, 83-92.
[52]
Shapira, F.; Shapira, S.; Kadar, T.; Cohen, G.; Chapman, S.; Raveh, L. Effects of CBDP and MEPQ on the toxicity and distribution of (3H) soman in mice. Arch. Toxicol., 1990, 64, 663-668.
[54]
Koelle, G.B. Protection of cholinesterase against irreversible inactivation by DFP in vitro. J. Pharmacol. Exp. Ther., 1946, 88, 323-327.
[55]
Koster, R. Synergisms and antagonisms between physostigmine and diisopropyl fluorophosphate in cats. J. Pharmacol. Exp. Ther., 1946, 88, 39-46.
[56]
Haigh, J.R.; Adler, M.; Apland, J.P.; Deshpande, S.S.; Barham, C.B.; Desmond, P.; Koplovitz, I.; Lenz, D.E.; Gordon, R.K. Protection by pyridostigmine bromide of marmoset hemidiaphragm acetylcholinesterase activity after soman exposure. Chem. Biol. Interact., 2010, 187, 416-420.
[57]
Kassa, J. Fusek, J. Bajgar, J. The importance of PANPAL pretreatment for survival of rats poisoned with supralethal dose of soman; Mini-CB Med. Treat. Sympos, 1997, pp. 26-30.
[58]
Kassa, J.; Musilek, K.; Koomlova, M.; Bajgar, J. A comparison of the efficacy of newly developed reversible inhibitors of acetylcholinesterase with commonly used pyridostigmine as pharmacological pre-treatment of soman-poisoned mice. Basic Clin. Pharmacol. Toxicol., 2012, 110, 322-326.
[59]
Koplovitz, I.; Harris, L.W.; Anderson, D.R.; Lennox, W.J.; Stewart, J.R. Reduction by pyridostigmine pretreatment of the efficacy of atropine and 2-PAM treatment of sarin and VX poisoning in rodents. Fundam. Appl. Toxicol., 1992, 18, 192-196.
[60]
Walter, K.; Muller, M.; Barkworth, M.F.; Niciecki, A.V.; Stanislaus, F. Pharmakokinetics of physostigmine in man following a single application of a transdermal system. Br. J. Clin. Pharmacol., 1995, 39, 59-63.
[61]
Kassa, J.; Vachek, J.; Bajgar, J.; Fusek, J. A comparison of the efficacy of pharmacological pretreatments against soman in mice. Vojen. Zdrav. Listy, 2001, 70, 22-25.
[62]
Nepovimova, E.; Korabecny, J.; Dolezal, R.; Nguyen, T.D.; Jun, D.; Soukup, O.; Pasdiorova, M.; Jost, P.; Muckova, L.; Malinak, D.; Gorecki, L.; Musilek, K.; Kuca, K. 7-methoxytacrine-4-pyridinealdoxime hybrid as a novel prophylactic agent with reactivation properties in organophosphate intoxications. Toxicol. Res., 2016, 5, 1012-1016.
[63]
Galli, A.; Mazri, A. Protection against diisopropylfluorophosphate intoxication by Meptazinol. Toxicol. Appl. Pharmacol., 1988, 95, 388-396.
[64]
Karlsson, B.M.; Koch, M.; Koskinen, L.O.D. Effects of soman in animals pretreated with nimodipine. Proceed. 6th CBW Protect. Symp., 1998Stockholm15-19 May 1998, pp. 181-184.
[65]
Stojiljkovic, M.P.; Maksimovic, M.; Bokonjic, D.; Kilibarda, V.; Tadic, V.; Boskovic, B. Adamantanes versus carbamatres as
prophylactic agents in soman-poisoned rats. 1998Proc. 6th CBW Protect. Symp., Stockholm10-15 May 1998, pp. 197-202.
[66]
Cho, Y. Protection by a transdermal patch system for the prophylaxis against soman poisonuing in Rhesus monkey. FASBJ, 2012, 26, 21-25.
[67]
Cho, Y.; Kim, W.S.; Hur, G.H.; Ha, Y.C. Minimum effective drug concentrations of a transdermal patch system containing procyclidine and physostigmine for prophylaxis against soman poisoning in rhesus monkeys. Environ. Toxicol. Pharmacol., 2012, 33, 1-8.
[68]
Myhrer, T.; Enger, S.; Aas, P. Soman-induced seizures in rats: Possible treatment and prophylaxis. In: Symposium Proceedings, NBC; , 2003. , 2003, Laihia, K., Ed.136-137
[69]
Kim, Y.B.; Cheon, K.C.; Hur, G.H.; Phi, T.S.; Yeon, G.B. Prophylactic effect of physostigmine and procyclidine against nerve-agent poisoning. Seventh Intl. Symp. Protect. CBWA., 2001Stockholm15-19 June 2001 Abstracts, p. 158.
[70]
Kim, Y.B.; Cheon, K.C.; Hur, G.H.; Phi, T.S.; Choi, S.J.; Hong, D.; Kang, J.K. Effects of combinational prophylactics composed of physostigmine and procyclidine on soman induced lethality, seizures and brain injuries. Environ. Toxicol. Pharmacol., 2002, 11, 15-21.
[71]
Loke, W.K.; Chua, E.; Loo, H.P.; Tan, S.H.; Teo, C. Anticonvulsant effects of post-intoxication administered atropine-clonidine drug combination in soman-poisoned rats. Seventh Intl. Symp. Protect. CBWA, 2001Stockholm15-19 June 2001 Abstracts, p. 160.
[72]
Tuovinen, K. Comparison of pyridostigmine, physostigmine, heptylphysostigmine and phosphotriesterase treatments in sarin intoxication. Suppl. Proceed. 6th CBW Protect. Symp., 1998Stockholm10-15 May 1998, p. 254.
[73]
Ashani, Y.; Peggins, J.O.; Doctor, B.P. Mechanism of inhibition of cholinesterases by huperzine A. Biochem. Biophys. Res. Commun., 1992, 184, 719-726.
[74]
Grunwald, J.; Raveh, L.; Doctor, B.P.; Ashani, Y. Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci., 1994, 54, 991-997.
[75]
Patočka, J.; Huperzine, A. An interesting anticholinesterase compound from the Chinese herbal medicine. Acta Med. (Hradec Kralove), 1998, 41, 155-157.
[76]
Lallement, G.; Baille, V.; Baubichon, D.; Carpentier, P.; Collombet, J.M.; Filliat, P.; Foquin, A.; Four, E.; Masqueliez, C.; Testylier, G.; Tonduli, L.; Dorandeu, F. Review of the value of huperzine as pretreatment of organophosphate poisoning. Neurotoxicology, 2002, 23, 1-5.
[77]
Raves, M.L.; Harel, M.; Pang, Y.P.; Silman, I.; Kozikowski, A.P.; Sussman, J.L. Structure of AChE complexed with the nootropic alkaloid, (-) huperzine A. Nat. Struct. Biol., 1997, 4, 57-63.
[78]
Saxena, A.; Qian, N.; Kovach, I.M.; Kozikowski, A.P.; Pang, Y.P.; Vellom, D.C.; Radic, Z.; Quinn, D.; Taylor, P.; Doctor, B.P. Identification of aminoacid residues involved in the binding of huperzine A to cholinesterases. Protein Sci., 1994, 3, 1770-1778.
[79]
Wang, Y.; Wei, Y.L.; Oguntayo, S.; Doctor, B.P.; Nambiar, M.P. (2013) A combination of (plus) and (minus)-Huperzine A impoves protection against soman toxicity compared to (plus)-Huperzine A in guinea pigs. Chem. Biol. Interact., 2013, 2013(203), 120-124.
[80]
Ago, Y.; Koda, K.; Takuma, K. Pharmacological aspects of the acetylcholinesterase iahibitor Galantamine. J. Pharmacol. Sci., 2011, 116, 6-17.
[81]
Bajgar, J. Protective effect of reversible cholinesterase inhibitors (tacrine, pyridostigmine) and EqBuChe against VX poisoning and brain acetylcholinesterase inhibition in rats. Acta Med. (Hradec Kralove), 2008, 51, 223-228.
[82]
Freeman, S.E.; Dawson, R.M. Tacrine: A pharmacological review. Prog. Neurobiol., 1991, 36, 257-277.
[83]
Korabecny, J.; Nepovimova, E.; Soukup, O.; Dolezal, R.; Jun, D.; Musilek, K.; Spilovska, K.; Babkova, K.; Malinak, D.; Gorecki, L.; Mezeiova, E.; Kuca, K. Novel tacrine inhibitors of acetylcholinesterase with potential impact against organophosphorous poisoning. Interdiscip. Toxicol., 2016, 9(Suppl. 1), 35.
[84]
Lau, W.M. Protection by tacrine and atropine against the depressant effects of soman in guinea pig atrium. Proceedings of the 4th International Symposium Protection Against Chemical Warfare Agents, 1992Stockholm8-12 June 1992 suppl. 1, , p. 182.
[85]
Lorke, D.E.; Hasan, M.Y.; Nurulain, S.M.; Shafiullah, M.; Kuca, K.; Petroianu, G.A. Acetylcholinesterase inhibitors as pretreatment before acute exposure to organophosphates: Assessment using methyl-paraoxon. CNS Neurol. Disord. Drug Targets, 2012, 11, 1052-1060.
[86]
Patočka, J.; Bajgar, J.; Fusek, J.; Bielavsky, J. Protective effect of 1,2,3,4- tetrahydro- 9-aminoacridine on acetylcholinesterase inhibition by organophosphorus inhibitors. Collect. Czech. Chem. Commun., 1976, 41, 2646-2649.
[87]
Villarroya, M.; García, A.G.; Marco-Contelles, J.; López, M.G. An update on the pharmacology of galantamine. Expert Opin. Investig. Drugs, 2007, 16, 1987-1998.
[88]
Benek, O.; Musilek, K.; Horova, A.; Dohnal, V.; Dolezal, R.; Kuca, K. Preparation, in vitro screening and molecular modelling of monoquaternary compounds related to the selective acetylcholinesterase inhibitor BW284c51. Med. Chem., 2015, 11, 21-29.
[89]
Che, M.M.; Chanda, S.; Song, J.; Doctor, B.P.; Rezk, P.E.; Sabrieka, P.; Perkins, M.W.; Sciuto, A.M.; Nambiar, M.P. Aerosolized scopolamine protects against microinstillation inhalation toxicity to sarin in guinea pigs. Toxicol. Mech. Methods, 2011, 21, 463-472.
[90]
Meshulam, Y.; Cohen, G.; Chapman, S.; Alkalai, D.; Levy, A. Prophylaxis against organophosphate poisoning by sustained release of scopolamine and physostigmine. J. Appl. Toxicol., 2001, 21(Suppl. 1), S75-S78.
[91]
Anderson, D.R.; Harris, L.W.; Woodard, C.L.; Lennox, W.I. The effect of pyridostigmine pretreatment on oxime efficacy against intoxication by soman and VX in rats. Drug Chem. Toxicol., 1992, 15, 285-294.
[92]
Gordon, R.K.; Haigh, J.R.; Garcia, G.E.; Feaster, S.R.; Riel, M.A.; Lenz, D.E.; Aisen, P.S.; Doctor, B.P. Oral administration of pyridostigmine bromide and huperzine A potects human whole blood cholinesterases from ex in vivo exposure to soman. Chem. Biol. Interact., 2005, 157, 239-246.
[94]
Kim, W.S.; Cho, Y.; Kim, J.C.; Huang, Z.Z.; Park, S.H.; Choi, E.K. Shin, S.; Kim, Y.B. Protection by a transdermal patch containing physostigmine and procyclidine of soman poisoning in dogs. Eur. J. Pharmacol., 2005, 525, 135-142.
[95]
Tuovinen, K.; Hanninen, O. Protection of mice against soman by pretreatment with eptastigmine and physostigmine. Toxicology, 1999, 139, 233-241.
[97]
Fusek, J.; Bajgar, J.; Vachek, J. The prophylactic antidote against nerve paralytic agents - PANPAL. 2000. Working Group TG, 003, 11-13. September 2000[The Hague.].
[98]
Fusek, J.; Bajgar, J.; Merka, V. Prophylaxe von Vergiftungen mit Nervenkampfstoffen (Ergebnisse einer klinischen Studie. Koord. Sanitatsdienst., 2006, 24, 48-53.
[99]
Fusek, J.; Bajgar, J.; Merka, V. Medikamentose Prophylaxe bei Vergiftungen mit Nervenkampfstoffen. Koord. Sanitatsdienst., 2007, 25, 41-47.
[100]
Bajgar, J.; Kuca, K.; Fusek, J.; Jun, D.; Bartosova, L. Cholinesterase reactivators as prophylactics against nerve agents. Curr. Bioact. Compd., 2010, 6, 2-8.
[101]
Bajgar, J.; Kassa, J.; Kuca, K.; Fusek, J.; Stetina, R. Antidotes against chemical warfare agents (CWA) in the Czech Army.(in
Czech) Urg. Med., 2010, 13, 12-14.
[102]
Fusek, J.; Bajgar, J.; Kassa, J.; Kuca, K.; Jun, D. Psychotomimetic agent BZ (3-quinuclidinyl benzilate). In: Handbook of Toxicology of Chemical Warfare Agents, Second Edition, ; Gupta, R.C., Ed.; Elsevier: AP, Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney, Tokyo, 2015; pp. 135-142.
[103]
Gmiro, V.E.; Serdyuk, S.E.; Veselkina, O.S. Comparison of pharmacological potency and safety of glutamic blocker IEM-1913 and memantine. Biull. Eksp. Biol. Med., 2015, 160, 80-83.
[104]
Pharmacopoeia Bohemica, 5th part, Prague, 2002. Grada Publishing
a.s. pp. 5081-5226.
[105]
Kassa, J.; Fusek, J. The influence of anticholinergic drug selection on the efficacy of antidotal treatment of soman-poisoned rats. Toxicology, 2000, 154, 67-73.
[106]
Musilek, K.; Lipka, L.; Racakova, V.; Kuca, K.; Jun, D.; Dohnal, V.; Dolezal, M. New methods in synthesis of acetylcholinesterase reactivators and evaluation of their potency to reactivate cyclosarin-inhibited AChE. Chem. Pap., 2006, 60, 48-51.
[107]
Kuca, K.; Cabal, J. Evaluation of newly synthesized reactivators of the brain cholinesterase inhibited by sarin nerve agent. Toxicol. Mech. Methods, 2005, 15, 247-252.
[108]
Tekes, K.; Hasan, M.Y.; Sheen, R.; Kuca, K.; Petroianu, G.; Ludanyi, K.; Kalasz, H. High-performance liquid chromatographic determination of the plasma concentration of K-27, a novel oxime-type cholinesterase reaktivator. J. Chromatogr. A, 2006, 1122, 84-87.
[109]
Handbook of Toxicology of Chemical Warfare Agents. Part VIII; Chapters 66-75. Second Edition, Gupta, R.C., Editor. Elsevier/AP,
Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris,
San Diego, San Francisco, Singapore, Sydney, Tokyo., 2015, pp. 979-1123.